Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent

The aim of the study was to assess the sorption capacity of Ustekinumab, a drug based on interleukins 12 (IL-12) and 23 (IL-23), when using it with a magnetocontrollable sorbent.

Materials and Methods. To reduce the concentration of proinflammatory cytokines (IL-12, IL-23), the blood of patients with psoriatic arthritis was passed through magnetocontrollable polyacrylamide granules (MPG) of spherical shape with the particle size of 10–100 µm, obtained by emulsion polymerization. Perfusion was performed through a 10 ml column equipped with an electromagnet, into which MPG with immobilized antibodies to IL-12 and IL-23 was added. Ustekinumab, a commercial drug with concentration of monoclonal antibodies equaling 0.2 mg per 1 ml of saline was used as the source of antibodies to these interleukins. The specific sorption capacity of MPG was determined using a column filled with the granules in a volume of 0.2 ml and inducing their subsequent interaction with 1 ml of IL-12 and IL-23 solutions with increasing concentrations. The heparinized blood of 10 patients with psoriatic arthritis of various degrees of activity, who had no parenteral administration of IL-12/IL-23 inhibitors (Ustekinumab) for 12 months, was subjected to in vitro treatment. The blood of 10 healthy donors was used as the control; the perfusion procedure was similar.

Results. Digital parameters were measured for each sample before and after the interaction between the sorbent and blood plasma. There was a significant decrease in cytokines from the baseline — by 99.8% (in donors) and by 99.9% (in patients). When using a carbon sorbent, their concentration decreases by 92.6% from the baseline. As a result of sorption, blood cell counts did not change reliably, which is an additional positive aspect of this procedure.

Conclusion. The maximum possible decrease in the level of cytokines has great practical importance, since they play a leading role in the pathogenesis of psoriatic arthritis. The use of a synthesized Ustekinumab-based sorbent is a highly effective way of removing them simultaneously from blood plasma.

1. Badokin V.V. On the classification of psoriatic arthritis. Klinicheskaya revmatologiya 1995; 1: 53–56.
2. Zborovskaya I.A., Bedina S.A., Mozgovaya E.E., Slusar O.P. Enzimnyy profil’ plazmy krovi u bol’nykh ankiloziruyushchim spondilitom i psoriaticheskim artritom. V kn.: Aktual’nye problemy sovremennoy revmatologii. Vypusk XXXIV [Enzymatic profile of blood plasma in patients with ankylosing spondylitis and psoriatic arthritis. In: Actual problems of modern rheumatology. Issue XXXIV]. Moscow: Planeta; 2018; p. 69–74.
3. Molochkov V.A., Badokin V.V., Albanova V.I., Volnukhin V.A. Psoriaz i psoriaticheskiy artrit [Psoriasis and psoriatic arthritis]. Moscow; 2007.
4. Toti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57(6): 1059–1068, https://doi.org/10.1016/j.jaad.2007.07.016.
5. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., Cats A., Dijkmans B., Olivieri I., Pasero G., Veys E., Zeidler H. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34(10): 1218–1227, https://doi.org/10.1002/art.1780341003.
6. Shibata S., Tada Y., Komine M., Hattori N., Osame S., Kanda N., Watanabe S., Saeki H., Tamaki K. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatol Sci 2009; 53(1): 34–39, https://doi.org/10.1016/j.jdermsci.2008.06.008.
7. Korsakova Yu.L., Stanislav M.L., Denisov L.N., Nasonov E.L. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-prakticheskaya revmatologiya 2013; 51(2): 170–180.
8. Nasonov E.L. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013; 552 p.
9. Simonova O.V., Smirnova L.A., Timin M.V. Otsenka bezopasnosti primeneniya genno-inzhenernoy biologicheskoy terapii u bol’nykh psoriaticheskim artritom. V kn.: Aktual’nye problemy sovremennoy revmatologii. Vypusk XXXIV [Assessment of the safety of genetic engineering biological therapy in patients with psoriatic arthritis. In: Actual problems of modern rheumatology. Issue XXXIV]. Moscow: Planeta; 2018; p. 108–110.
10. Dolgikh T.I., Pyanova L.G., Baklanova O.N., Dolgikh V.T., Luzyanova L.S., Filippov S.I., Sokolova T.F., Salanov A.N., Glushchenko A.V., Yershov A.V., Reis B.A., Likholobov V.A. Cytokine adsorption onto the modified carbon sorbent surface in vitro in peritonitis. Obshchaya reanimatologiya 2009; 6: 66–69, https://doi.org/10.15360/1813-9779-2009-6-66.
11. Gontar I.P., Zborovskiy A.B., Levkin S.V., Sycheva G.F. Method of magnetic polyacrylamide granule producing. Patent RU 1582657. 1993.
12. Gontar I.P., Emelyanova O.I., Rusanova O.A., Maslakova L.A., Zborovskaya I.A. Method of simultaneous removal of interleukin-12 and interleukin-23 from biological fluids using magnetically controlled granules. Patent RU 2670674. 2018.

Gontar I.P., Emelyanova O.I., Rusanova O.A., Zborovskaya I.A. Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent. Sovremennye tehnologii v medicine 2020; 12(4): 72, https://doi.org/10.17691/stm2020.12.4.09